Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial

IMPORTANCE: Treatment options for patients with disease progression after treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1) are limited. Tucatinib is an oral, potent, human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor (TKI) being developed...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Oncol
Autori principali: Borges, Virginia F., Ferrario, Cristiano, Aucoin, Nathalie, Falkson, Carla, Khan, Qamar, Krop, Ian, Welch, Stephen, Conlin, Alison, Chaves, Jorge, Bedard, Philippe L., Chamberlain, Marc, Gray, Todd, Vo, Alex, Hamilton, Erika
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2018
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143009/
https://ncbi.nlm.nih.gov/pubmed/29955792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.1812
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi